Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Net Income (2022 - 2025)

Historic Net Income for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to -$54.9 million.

  • Centessa Pharmaceuticals' Net Income fell 2895.5% to -$54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.7 million, marking a year-over-year decrease of 5049.64%. This contributed to the annual value of -$235.8 million for FY2024, which is 5604.26% down from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Net Income of -$54.9 million as of Q3 2025, which was down 2895.5% from -$50.3 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Net Income registered a high of -$24.9 million during Q2 2023, and its lowest value of -$111.3 million during Q4 2024.
  • For the 4-year period, Centessa Pharmaceuticals' Net Income averaged around -$49.0 million, with its median value being -$43.8 million (2024).
  • In the last 5 years, Centessa Pharmaceuticals' Net Income soared by 6151.31% in 2023 and then crashed by 20222.06% in 2024.
  • Centessa Pharmaceuticals' Net Income (Quarter) stood at -$43.2 million in 2022, then rose by 14.68% to -$36.8 million in 2023, then crashed by 202.22% to -$111.3 million in 2024, then surged by 50.69% to -$54.9 million in 2025.
  • Its last three reported values are -$54.9 million in Q3 2025, -$50.3 million for Q2 2025, and -$26.1 million during Q1 2025.